Multifunctional Ackermania muciniphila Amuci-5 strain and application thereof

By providing Amuci-5 and its progeny strains, cloned strains and pure cultures, the problem of development of multiple-efficacy Amuci-1 mucophila strains in the prior art is solved, and the multi-purpose strains have been achieved Multiple therapeutic effects of the disease, including cholesterol degradation, fat suppression, anti-diarrhea and enteritis improvement, demonstrated the multifunctional probiotic potential of this strain.

CN119060873APending Publication Date: 2024-12-03SICHUAN ANAEROBIC BIOTECHNOLOGY CO LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202410726263.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-04-17
Filing Date
2024-06-06
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The prior art is difficult to develop a strain of Akmanella mucophilin that can have multiple functions for multiple diseases such as obesity, diabetes, cardiovascular disease and inflammation, and functional differences between different strains affect their treatment. potential and effect.

Method used

Akkermansia muciniphila Amuci-5, and its progeny strains, cloned strains and pure cultures, including its inactivated bacterial bodies, are provided for preparation of drugs. , health care products or food compositions for lowering cholesterol, inhibiting fat formation, resisting chemotherapy-related diarrhea and improving radioactive intestinal injury.

Benefits of technology

The strain showed significant cholesterol degradation ability, fat inhibition effect, anti-diarrhea and enteritis improvement ability, and was safe and able to be used as a multifunctional probiotic strain to prevent and treat a variety of diseases, simplify treatment options and reduce medical costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119060873A_ABST
    Figure CN119060873A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of microorganisms, and discloses a multifunctional Ackermann muci-5 strain with the preservation number of CCTCC (China Center For Type Culture Collection) NO: M 2024050 and application of the multifunctional Ackermann muci-5 strain. The strain has multiple functions of improving glycolipid metabolism, controlling body weight, improving diarrhea and radioactive intestinal injury and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of microorganisms, and particularly relates to a multifunctional Akkermansia muciniphila and an application thereof. Background Art

[0002] Akkermansia muciniphila (Akkermansia muciniphila) is a mucin-degrading bacterium found in the intestines of humans and many other animals. It belongs to the phylum Verrucomicrobiota, class Verrucomicrobiae, order Verrucomicrobiales, family Akkermansiaceae. Akkermansia muciniphila is an oval, gram-negative anaerobic bacterium, strain MucT was isolated by Derrien in 2004.

[0003] The main characteristic of Akk bacteria is that they can use the intestinal mucus on the surface of the intestinal epithelium as their carbon source, nitrogen source and growth energy source. It colonizes at different stages of the intestine. In infancy, Akk bacteria can be used as a marker of the growth status and diversity of the intestinal flora, and their number increases significantly from early life to adulthood. Akk bacteria are negatively correlated with obesity, diabetes, cardiovascular disease and low-grade inflammation. They can protect the integrity of intestinal epithelial cells and mucus layer, play a metabolic protective role, and play an anti-inflammatory role through multiple mechanisms during the inflammatory response.

[0004] In addition, Akkermansia has shown potential in the treatment of metabolic disorders, including obesity, diabetes, and metabolic-associated fatty liver disease (MAFLD). Studies have shown that Akkermansia treatment can effectively reverse MAFLD in the liver, such as hepatic steatosis, inflammation, and liver damage, and these therapeutic effects persist after long-term discontinuation of the drug. Akkermansia maintains the integrity of the intestinal barrier and reshapes the composition of the intestinal flora to treat MAFLD in mice by increasing L-aspartate levels in the gut-liver axis, activating the LKB1-AMPK axis, increasing lipid oxidation and bile acid metabolism in the gut-liver axis, leading to reduced lipid accumulation and oxidative stress-induced apoptosis.

[0005] Akk bacteria also show potential in treating type 2 diabetes and obesity. Studies have shown that Akk bacteria are expected to become the next generation of probiotics after lactic acid bacteria and bifidobacteria. In addition, Akk bacteria also show positive effects in improving the learning and cognitive function of mice, symptoms of ALS, colitis, and preventing the occurrence of related intestinal cancer.

[0006] Different strains of Akk bacteria may show functional differences, which may be caused by a variety of factors, such as genomic diversity, differences in metabolic pathways, differences in environmental adaptability, host specificity, genetic variation, phenotypic plasticity, etc. These factors work together to lead to functional differences between different Akk strains, which in turn may affect their potential and effectiveness in disease treatment and health maintenance.

[0007] A strain with multiple functions can have multiple positive effects on the host's health at the same time, such as improving metabolic syndrome, enhancing immune function and promoting digestive health. Using a single strain to achieve multiple therapeutic effects can improve the efficiency of treatment and reduce the number of different probiotics that patients need to take, thereby simplifying treatment plans, reducing costs, and reducing time and resource consumption in the research and development process.

[0008] Therefore, developing strains with multiple functions is of great significance for improving treatment effects, simplifying treatment plans, reducing medical costs and promoting the development of personalized medicine. Summary of the invention

[0009] The purpose of the present invention is to provide a multifunctional Akkermansia muciniphila and application thereof.

[0010] As a first aspect of the present invention, the present invention provides an Akkermansia muciniphila Amuci-5 with a deposit number of CCTCC NO: M2024050 or its progeny strain, cloned strain and pure culture.

[0011] In some embodiments, the present invention provides an inactivated bacterial cell of Akkermansia muciniphila Amuci-5 with a deposit number of CCTCC NO: M 2024050 or its progeny strains, cloned strains and pure cultures.

[0012] As a second aspect of the present invention, the present invention provides a method for culturing Akkermansia muciniphila Amuci-5 or its progeny strains, cloned strains and pure cultures, the method comprising inoculating Akkermansia muciniphila Amuci-5 or its progeny strains, cloned strains and pure cultures into a culture medium, performing proliferation culture, and obtaining proliferated Akkermansia muciniphila.

[0013] As a third aspect of the present invention, the present invention provides a food composition, a health product composition or a pharmaceutical composition, which contains Akkermansia muciniphila Amuci-5 or its progeny strains, cloned strains and pure cultures, or contains inactivated bacteria of Akkermansia muciniphila Amuci-5 or its progeny strains, cloned strains and pure cultures.

[0014] As a fourth aspect of the present invention, the present invention provides the use of Akkermansia muciniphila Amuci-5 or its progeny strains, cloned strains and pure cultures in the preparation of drugs, which are used alone or in combination with other probiotics or in combination with other drugs to lower cholesterol, or prevent / treat obesity, or prevent / treat diarrhea caused by anti-tumor drugs, or prevent / treat radiation intestinal damage (also known as radiation enteritis), or prevent / treat diarrhea caused by radiotherapy.

[0015] In some embodiments, the diarrhea caused by the anti-tumor drug is chemotherapy-related diarrhea.

[0016] In some embodiments, the chemotherapy-related diarrhea is diarrhea caused by drugs whose active ingredients are selected from one or more of the following: 5-fluorouracil, tegafur, 5'-2'-deoxyuridine, capecitabine, S-1, paclitaxel, docetaxel, vinorelbine, cisplatin, carboplatin, nedaplatin, oxaliplatin, lobaplatin, cyclophosphamide, ifosfamide, melphalan, carmustine, and irinotecan.

[0017] As a fifth aspect of the present invention, the present invention provides the use of Akkermansia muciniphila Amuci-5 with a deposit number of CCTCC NO: M 2024050 or its progeny strains, cloned strains and pure cultures inactivated bacteria in the preparation of a health product composition or a pharmaceutical composition for weight loss.

[0018] The Akkermansia muciniphila of the present invention has no virulence factors and drug-resistant genes, has good safety, has multiple functions such as lowering cholesterol, inhibiting fat formation, resisting chemotherapy-related diarrhea, and improving radiation-induced intestinal damage, and is a potential multifunctional probiotic strain.

[0019] Microbiological deposit information

[0020] Strain name: Akkermansia muciniphila Amuci-5

[0021] Storage time: January 9, 2024

[0022] Depository: China Center for Type Culture Collection (CCTCC), Wuhan University, Wuhan, Hubei, China, Postal Code: 430072, Tel: 027-68754052

[0023] Deposit number: CCTCC NO: M 2024050. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 These are the results of a test on the cholesterol degradation ability of Akkermansia muciniphila Amuci-5.

[0025] Figure 2 The oil red-O staining was used to detect the effect of strain Amuci-5 on 3T3-L1 cell adipogenesis. A is the oil red-O staining picture of each group; B is the relative amount of lipid accumulation in each group of cells based on the model group.

[0026] Figure 3 This is a graph showing the inhibitory effect of live Akkermansia muciniphila Amuci-5 on zebrafish fat synthesis.

[0027] Figure 4 This is a diagram showing the inhibitory effect of inactivated Akkermansia muciniphila Amuci-5 on zebrafish fat synthesis.

[0028] Figure 5 This is a graph showing the effect of live Akkermansia muciniphila Amuci-5 on improving the body weight of DIO mice. A: Body weight at the end of the experiment; B: Weight gain at the end of the experiment; C: Weight change rate at the end of the experiment.

[0029] Figure 6 This is a graph showing the effect of live Akkermansia muciniphila Amuci-5 on improving fat mass in DIO mice. A fat mass; B fat body ratio; C lean meat mass; D lean meat / body weight ratio.

[0030] Figure 7 This is a graph showing the effect of live Akkermansia muciniphila Amuci-5 on improving glucose tolerance in DIO mice. A is a graph showing blood glucose concentration at different time points after intragastric administration of glucose; B is the area under the curve (AUC).

[0031] Figure 8 This is a graph showing the effect of inactivated Akkermansia muciniphila Amuci-5 on improving the body weight of DIO mice. A: Body weight at the end of the experiment; B: Weight gain at the end of the experiment; C: Weight change rate at the end of the experiment.

[0032] Fig. 9This is a graph showing the effect of inactivated Akkermansia muciniphila Amuci-5 on improving fat mass in DIO mice. A fat mass; B fat body ratio; C lean meat mass; D lean meat / body weight ratio.

[0033] Fig.10 This is a graph showing the effect of inactivated Akkermansia muciniphila Amuci-5 on improving glucose tolerance in DIO mice. A. Blood glucose concentration curve at various time points after intragastric glucose administration; B. Area under the curve (AUC); C. Blood glucose concentration 30 minutes after intragastric glucose administration; D. Blood glucose concentration 60 minutes after intragastric glucose administration.

[0034] Fig.11 This is the therapeutic effect of Akkermansia muciniphila Amuci-5 on 5-Fu-induced diarrhea in mice; A is the diarrhea score graph, B is the total diarrhea score graph.

[0035] Fig.12 The figures are as follows: A is the diarrhea score curve of each group from day 1 to day 9; B is the total diarrhea score of each group on day 9; C is the diarrhea score graph of each group on day 5.

[0036] Fig.13 This is a graph showing the effect of live Akkermansia muciniphila Amuci-5 on improving blood cells in mice with radiation enteritis. A is the percentage of lymphocytes; B is the percentage of neutrophils; C is the percentage of monocytes; and D is the number of red blood cells.

[0037] Fig.14 This is a 21-day subacute toxicity test on live and killed bacteria of Akkermansia muciniphila Amuci-5. Body weight chart: A. Body weight of male mice; B. Body weight of female mice. DETAILED DESCRIPTION

[0038] The specific accession number for which the present invention is claimed strain , which means but is not limited to:

[0039] (1) strains with specific accession numbers deposited in the above-mentioned depository;

[0040] (2) a strain having the same genome as the strain described in (1);

[0041] (3) A subculture strain without mutation based on the above (1) or (2);

[0042] (4) strains based on (1), (2) or (3) above that have accumulated minor mutations during subculture but have no substantial changes in toxicity, immunogenicity or biological activity;

[0043] (5) Live bacteria, inactivated forms, lysates or fermentation products of any of the strains described in (1) to (4) above.

[0044] As is known in the art, minor mutations are inevitably introduced into strains through passage and application. When mutations occur in non-coding sequence regions or synonymous mutations in coding regions or mutations that do not affect the toxicity, immunogenicity and biological activity of the strain (for example, it may be a connecting amino acid residue between two domains, or a residue with minor mutations located inside the higher-level structure of a protein that does not contact immune cells and does not affect toxicity, immunogenicity and biological activity), it can be reasonably expected that when these minor changes do not significantly affect the toxicity, immunogenicity and biological activity of the offspring strains, the purpose of the present invention can still be achieved, and they are derived from the strains contributed by the present invention, and therefore are still within the scope of the substantial technical contribution of the present invention. These minor mutations are still non-substantial mutations and should be regarded as mutant strains with no changes in toxicity, immunogenicity and biological activity.

[0045] There is no substantial change in toxicity, immunogenicity and biological activity, including but not limited to, within the limits of detection technology such as detection sensitivity and detection limit and acceptable or unavoidable errors, the toxicity, immunogenicity and biological activity are considered to be the same. When the toxicity, immunogenicity and biological activity of the offspring of the strain are measured using cells and animals, there is no substantial change due to differences in cell strains, animal species, age, sex, health status, culture conditions, etc., as well as foreseeable or unavoidable systematic errors.

[0046] The present invention also provides a progeny strain, a cloned strain or a pure culture of the Akkermansia muciniphila strain.

[0047] Progeny strains It refers to the offspring strains produced by the process of microbial subculture. In the cultivation and research of microorganisms, in order to maintain the genetic stability and biological characteristics of the strains, the strains are subcultured. Subculture refers to the process of taking a strain out of the culture medium in which it grows and inoculating it into a new culture medium so that it continues to grow and reproduce. In this process, the strains obtained each time can be called progeny strains.

[0048] Cloning strains It refers to strains with the same genetic characteristics that are separated from a single cell or microbial population through cloning technology and cultured and amplified. The characteristics of cloned strains are consistent genetic background and can maintain specific biological characteristics and functions.

[0049] Pure culture A pure culture is a culture consisting of a single species of microorganism. A pure culture means that all the microorganisms growing on the culture medium are descendants of the same microorganism and have the same genetic characteristics.

[0050] Live bacteriaIt refers to microorganisms that have the ability to carry out life activities, metabolism, growth and reproduction, and can form colonies under suitable environmental conditions. These colonies can be confirmed by visible growth on the culture medium.

[0051] Inactivated bacteria / inactivated bacteria It refers to microorganisms that have lost their ability to survive and are unable to metabolize, grow or reproduce due to heat treatment, chemical disinfectants, radiation or other physical or chemical methods.

[0052] The present invention also provides a food, a health product or a pharmaceutical composition, which contains the aforementioned Akkermansia muciniphila strain or the Akkermansia muciniphila strain obtained by the aforementioned culture method.

[0053] In some specific embodiments, a single administration of a food, health product or pharmaceutical composition to a subject contains 10 2 ~10 15 CFU, 10 3 ~10 14 CFU, 10 4 ~10 13 CFU, 10 5 ~10 12 CFU, 10 6 ~10 12 CFU, 10 7 ~10 11 CFU, 10 8 ~10 10 CFU, or 10 8 ~10 10 CFU of Akkermansia muciniphila.

[0054] The present invention provides a composition in the form of a common food, health product, or medicine, which contains the muciniphilic Akkermansia of the present invention. These common foods, health products, or medicines contain various exemplary embodiments of the composition of the present invention. These common foods, health products, or medicines can be made or provided as probiotic powders, capsules, cereals, baby food, health food or food for specific health purposes, and can also be pharmaceutical capsules, tablets, powders, etc.

[0055] The probiotic composition of the present invention may further contain other beneficial ingredients, such as another functional probiotic, prebiotic or medicine, etc. Examples of other beneficial ingredients include, but are not limited to, Bacillus licheniformis, Bifidobacterium, Clostridium butyricum, fructooligosaccharides, galacto-oligosaccharides, isomaltooligosaccharides, xylo-oligosaccharides, manno-oligosaccharides, inulin, stachyose, soybean oligosaccharides, β-glucan, lactofructooligosaccharides, etc.

[0056] The specific temperature parameters in the present invention, unless otherwise specified, should be understood as constant temperature treatment, and are allowed to fluctuate within a certain temperature range, such as within the range of ±5°C, ±4°C, ±3°C, ±2°C, and ±1°C.

[0057] The technical solutions in the embodiments of the present invention will be described clearly and completely below in conjunction with the accompanying drawings. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative work should fall within the scope of protection of the present invention.

[0058] The culture medium used in the following examples is prepared as follows. If not otherwise specified, it can be purchased commercially or prepared according to a common method in the art:

[0059] Preparation of anaerobic BHI & mucin liquid medium: weigh 38.5g of BHI broth powder (HB8297-1, Qingdao Haibo Biotechnology Co., Ltd.) and 2g of mucin (M2378-100G, Sigma-Aldrich Trading Co., Ltd.), dissolve in 1L of distilled water, deoxygenate with N2 replacement and dispense, sterilize at 121℃ for 15min, and store in a cool, dry place. If preparing solid culture medium, add 15g of agar powder.

[0060] Preparation of anaerobic BHI & mucin liquid culture medium containing cholesterol: Weigh 0.5 g of cholesterol (Sigma-Aldrich Trading Co., Ltd., C8667), add it to 25 mL of Tween 80 (Shanghai MacLean Biochemical Technology Co., Ltd., T6336), heat it in a 90°C water bath until the cholesterol is dissolved (about 40 to 60 minutes), then add this mixture to the packaged anaerobic BHI & mucin liquid culture medium at a ratio of 2.5% (v / v), sterilize it at 121°C for 15 minutes, and store it in a cool and dry place.

[0061] Preparation of anaerobic saline: Weigh 8.5g of sodium chloride and dissolve it in 1L of pure water, stir and boil. After boiling, use a Hungate apparatus to pass N2 for 20 minutes. After cooling to room temperature, divide the culture medium into anaerobic bottles that have been deoxygenated with N2 for 121 minutes and sterilize at high temperature for 15 minutes.

[0062] Preparation of culture medium for bacterial powder: weigh 10g of anhydrous glucose, 2g of N-acetylglucosamine, 20g of tryptone, 10g of casein, 5g of yeast extract, 5g of soy peptone, 2g of threonine, 1g of serine, 2g of potassium dihydrogen phosphate, 2g of dipotassium hydrogen phosphate, 0.5g of sodium bicarbonate, 0.1g of manganese sulfate, 0.05g of calcium chloride, 0.5mL of Tween 80, and 0.5g of monohydrated cysteine ​​hydrochloride, dissolve in 1L of distilled water, deoxygenate with N2, dispense, and sterilize at 121℃ for 20min. Store in a cool and dry place.

[0063] Example 1 Isolation and identification of strains

[0064] Fresh fecal samples from healthy volunteers were collected, resuspended in appropriate amount of anaerobic PBS, shaken, and filtered. Under N2 protection, the samples were gradient diluted and anaerobically cultured for 5-9 days. The cultured strains were deduplicated by MALDI-TOF mass spectrometry and then amplified and sequenced by 16S rDNA gene (Beijing Qingke Biotechnology Co., Ltd. Chengdu Branch) for identification. The sequencing results were compared by BLAST, and finally 3 strains of Akkermansia muciniphila were isolated, named Amuci-5, Amuci-7 and Amuci-8.

[0065] Amuci-5 was deposited in the China Center for Type Culture Collection (CCTCC, Wuhan University Collection Center) on January 9, 2024, with the accession numbers: CCTCC NO: M 2024050.

[0066] Example 2 Whole genome analysis

[0067] Amuci-5 was inoculated into 5 mL of anaerobic BHI & mucin liquid medium and cultured until the late logarithmic growth period. The whole genome DNA of the strain was extracted for whole genome sequencing. After quality control of the offline data, it was assembled and annotated using conventional methods, and the obtained protein sequence was compared with the VFDB (Virulence Factor Databases) and CARD (The ComprehensiveAntibiotic Resistance Database) databases to conduct virulence factor and drug resistance gene analysis. The results showed that the bacteria were safe at the genetic level.

[0068] The novelty of the strain was analyzed using Average Nucleotide Identity (ANI) and SNP-based Variant analysis. By searching in Genbank, 307 publicly available Akkermansia muciniphila-related whole genomes were found. By comparing with fastANI (v1.33) and snippy (v4.6.0), the strains with the closest ANI to Amuci-5 and the related Variant information are shown in Table 1 below, indicating that Amuci-5 is a new strain:

[0069] Table 1 Strain genome ANI and variant information

[0070] strain Genome assembly name ANI (%) Total Variant Amuci-5 ASM288537v1 99.89 934

[0071] Example 3 Cholesterol degradation experiment

[0072] The preserved Amuci-5 was inoculated into 5 mL of anaerobic BHI & mucin liquid medium, and the standard strain of Akkermansia muciniphila (CICC24917, China Industrial Microbiological Culture Collection Management Center, same as ATCC BAA-835) was used as the reference strain. All strains were cultured anaerobically at 37°C until the late logarithmic growth period to obtain activated strains. Each activated strain was inoculated into 1 mL of anaerobic BHI & mucin liquid medium containing cholesterol, with 3 parallels set for each group, and the cholesterol content was detected after anaerobic culture at 37°C for 72 hours.

[0073] Take 1mL of culture solution and centrifuge at 5000rpm for 10min, and take the supernatant to obtain the test sample. Use the total cholesterol (TC) content detection kit (Beijing Solebow Technology Co., Ltd., BC1985) to draw a standard curve and detect the total cholesterol content according to the instructions of the kit. The cholesterol degradation rate is calculated as follows: cholesterol degradation rate % = (cholesterol content in blank culture medium - cholesterol content in experimental group) / cholesterol content in blank culture medium × 100%. For the cholesterol degradation ability results of the reference strain and the test strain, see Figure 1 The results were expressed as Mean±SD, and T-test was used for comparative analysis. ** represents p<0.01.

[0074] Depend on Figure 1 It can be seen that the cholesterol degradation ability of Amuci-5 is significantly higher than that of the reference strain CICC24917 (**, p<0.01), indicating that Amuci-5 has a strong cholesterol degradation ability.

[0075] Example 4 Detection of the effect of strain Amuci-5 on adipogenesis of 3T3-L1 cells by oil red-O staining

[0076] Oil Red O staining is a method for measuring the amount of fat produced in cells by staining differentiated 3T3-L1 cells with Oil Red O reagent.

[0077] Strain culture: Inoculate Amuci-5 and standard strain CICC24917 from the bacterial storage into 15mL of bacterial powder preparation medium, and culture anaerobically in a 37℃ electric constant temperature incubator for 48h to obtain activated strains. Transfer the activated strain to 360mL of bacterial powder preparation medium and culture anaerobically for 48h. Collect the bacterial solution, centrifuge at 7000rpm / min for 15min, and wash the bacteria once with sterile PBS. After pasteurization, place at 4℃ for use.

[0078] Cell inoculation: 3T3-L1 cells (Wuhan Pronocell Life Science Co., Ltd., CL-0006) with good growth status and appropriate density were digested with trypsin (Beijing Lanjieke Technology Co., Ltd., BL501A), collected by centrifugation, and diluted to 3×10 with DMEM complete medium (Thermo Fisher Scientific, C11995500BT) containing 10% FBS and 1% PS (Thermo Fisher Scientific, 15140-122). 5 Each well was inoculated with 2 mL of cells / mL in a 6-well plate. The day of inoculation was recorded as Day 0.

[0079] Preparation of adipogenic inducing agent:

[0080] Inducer I: weigh 25 mg of dexamethasone (Sigma-Aldrich (Shanghai) Trading Co., Ltd., D1756), resuspend and mix with 12.74 mL of DMSO to make the concentration 5 mM; weigh 100 mg of rosiglitazone (Kaman Chemical Company, 71740), resuspend and mix with 139.89 mL of DMSO to make the concentration 2 mM; weigh 250 mg of IBMX (Sigma-Aldrich (Shanghai) Trading Co., Ltd., I5879), resuspend and mix with 2.25 mL of DMSO to make the concentration 0.5 M; weigh 25 mg of insulin (MCE Biotechnology Co., Ltd., USA, HY-P0035), resuspend and mix with 2.5 mL of DMSO to make the concentration 10 mg / mL. Dilute the above drugs 1000 times and add them to 100 mL of DMEM complete medium to make the final concentrations 5 μM, 2 μM, 0.5 mM and 10 μg / mL respectively.

[0081] Inducer II: Pipette 100 μL of 2 mM rosiglitazone and 100 μL of 10 mg / mL insulin, and add them to 100 mL of DMEM complete medium to make the final concentrations 2 μM and 10 μg / mL, respectively.

[0082] Cell adipogenesis induction and drug administration: This experiment was divided into the following groups: model group, standard strain CICC24917 group and Amuci-5 group. The treatment methods for different groups were as follows: On Day 3, the model group was added with the inducer I prepared in advance, and the other groups were added with the inactivated bacteria solution resuspended with the inducer I to a concentration of 5×10 8 / mL. Placed in a 5% carbon dioxide incubator and cultured at 37°C. On Day 5, 7, 9, 11, and 13, the model group was added with the inducer II prepared in advance, and the other groups were added with the inactivated bacteria solution resuspended with the inducer II to a concentration of 5×10 8 The cells / mL were placed in a 5% carbon dioxide incubator and cultured at 37°C.

[0083] 3T3-L1 cell staining treatment: On Day 15, the cell supernatant was discarded, 4% paraformaldehyde (Beijing Lanjieke Technology Co., Ltd., BL539A) was added to fix for 30 minutes, and sterile PBS (Wuhan Boster Biotechnology Co., Ltd., PYG0021) was used to wash twice, 60% isopropanol (Sangon Biotechnology (Shanghai) Co., Ltd., A507048-0500) solution was added to stand for 3 minutes, and Oil Red O dye solution (Beijing Solebold Technology Co., Ltd., G1260) was added for staining. After the staining, 60% isopropanol solution was added to observe the intercellular space under a microscope. The intercellular space was clear, and sterile PBS was added to wash twice, and the cells were photographed under a microscope. After the end, isopropanol was added to dissolve the lipid droplets stained with Oil Red O solution, and the absorbance at 500nm was measured using an enzyme reader. The results are expressed as Mean±SD, and One-way ANOVA was used for multiple comparison analysis. ***, compared with the model group, p<0.001; **, compared with the model group, p<0.01; ##, compared with the standard strain CICC24917, p<0.01.

[0084] Experimental results: Figure 2 As shown, through microscopic observation, compared with the model group, the Amuci-5 group significantly reduced intracellular lipid droplets and fat accumulation (p<0.001), and the effect was significantly better than that of the standard strain CICC24917 (p<0.01).

[0085] Example 5 Cultivation and preparation of Akkermansia muciniphila

[0086] Lyophilization protective agent preparation:

[0087] Solution A: sucrose 5g, trehalose 5g, mannitol 5g, skim milk powder 8g, purified water 62g; sterilize at 115℃ for 20min.

[0088] Solution B: 3g of sodium vitamin C, 12g of purified water. Filter and sterilize for later use.

[0089] When using, mix in a mass ratio of A:B=17:3.

[0090] Preparation of bacterial powder: The preserved Akkermansia muciphila Amuci-5, Amuci-7 and Amuci-8 were inoculated into the bacterial powder preparation medium respectively to obtain the first-level seed liquid. Subsequently, the second-level seed liquid was transferred again. The second-level seed liquid was pumped into the fermentation tank, and the fermentation parameters (37°C, pH 6.0, 100rpm, 0.06MPa) were set for fermentation and culture. After the fermentation reached the end point, the bacteria were collected by centrifugation. Lyophilization protective agent was added at a weight ratio of 1:1 to 1:2 between the bacterial mud and the lyophilization protective agent, and the emulsified bacterial mud was mixed. The emulsified bacterial suspension was freeze-dried and crushed to obtain bacterial powder.

[0091] Example 6 Akkermansia muciphila Amuci-5 inhibits zebrafish fat synthesis

[0092] Preparation of bacterial suspension: Take 2×10 of the live Akkermansia muciniphila Amuci-5, Amuci-7, and Amuci-8 powders from Example 5. 9 CFU were fully dissolved in 2 mL of saline to make a concentration of 1×10 9 CFU / mL of bacterial suspension.

[0093] Experimental grouping and drug administration: 180 5dpf melanin allele mutant Albino zebrafish (purchased from Hangzhou Huante Biotechnology Co., Ltd.) were randomly divided into 6 groups, namely normal control group, model control group, orlistat group, Amuci-5 group, Amuci-7 group and Amuci-8 group, 30 fish in each group (purchased from Hangzhou Huante Biotechnology Co., Ltd.). The normal control group and the model control group were given PBS solution, the positive control orlistat group was given orlistat at a concentration of 15.0μg / mL (Shandong Xinshidai Pharmaceutical Co., Ltd.), and the Akkermansia muciniphila in each group was prepared by adding the above bacterial suspension to 18ml PBS, that is, the concentration was 1×10 8CFU / mL mucinophilic Akkermansia, the final volume of zebrafish solution in each group was 20mL, and after incubation at 28℃ for 1h, except for the normal control group, all other groups were fed with high-fat food (egg yolk powder, 38% glyceride, 19% lecithin, 30% protein, a small amount of cholesterol, sugar, minerals, etc.), and then continued to incubate at 28℃ for 24h. After the experiment, oil red O fat staining was performed (Oil Red O is a strong lipid solvent and lipid dye that can combine with neutral fat droplets such as triglycerides to form an orange-red color, which can quantitatively reflect the fat content in the intestine and blood vessels of zebrafish). Ten zebrafish were randomly selected from each group and photographed under a dissecting microscope to analyze the fat staining intensity of the intestine and tail blood vessels. The results are expressed as Mean±SEM, and one-way ANOVA was used for multiple comparison analysis. Compared with the model group, ***p<0.001.

[0094] The results are as follows Figure 3 As shown, Akkermansia muciniphila Amuci-5, Amuci-7, and Amuci-8 can all reduce the fat content in zebrafish, but there is no significant difference compared with the model control group. Amuci-5 is slightly better than Amuci-7 and Amuci-8.

[0095] Example 7 Inactivation of Akkermansia muciniphila Amuci-5 inhibits zebrafish fat synthesis

[0096] Preparation of inactivated bacterial suspension: Take 2×10 of the live Akkermansia muciniphila Amuci-5, Amuci-7, and Amuci-8 powders from Example 5. 9 CFU were fully dissolved in 2 mL of saline to make a concentration of 1×10 9 CFU / mL bacterial suspension was then pasteurized in a water bath at 80°C for 30-60 min to obtain an inactivated bacterial suspension.

[0097] Experimental grouping and drug administration: 210 zebrafish of the Albino strain with melanin allele mutant at 5 dpf (purchased from Hangzhou Huante Biotechnology Co., Ltd.) were randomly divided into 7 groups, namely normal control group, model control group, orlistat group, inactivated CICC24917 group, inactivated Amuci-5 group, inactivated Amuci-7 group and inactivated Amuci-8 group, with 30 fish in each group. The normal control group and the model control group were given PBS solution, the positive control orlistat group was given orlistat at a concentration of 15.0 μg / ml (purchased from Shandong New Era Pharmaceutical Co., Ltd.), and the inactivated CICC24917 group was given a concentration of 1×10 8 CFU / mL inactivated Akkermansia muciniphila standard strain CICC24917. The inactivated Akkermansia muciniphila suspension in each group was added with 18 mL PBS to give a concentration of 1×10 8CFU / mL of Akkermansia muciniphila, the final volume of zebrafish solution in each group was 20mL. After incubation at 28℃ for 1h, except for the normal control group, all other groups were fed with high-fat food (egg yolk powder, 38% glyceride, 19% lecithin, 30% protein, a small amount of cholesterol, sugar, minerals, etc.), and then incubated at 28℃ for 24h. After the experiment, oil red O fat staining was performed (Oil Red O is a strong lipid solvent and lipid dye that can combine with neutral fat droplets such as triglycerides to form an orange-red color, which can quantitatively reflect the fat content in the intestine and blood vessels of zebrafish). Ten zebrafish were randomly selected from each group and photographed under a dissecting microscope to analyze the fat staining intensity of the intestine and tail blood vessels. The results are expressed as Mean±SEM, and one-way ANOVA was used for multiple comparison analysis. Compared with the model group, *p<0.05; ***p<0.001.

[0098] Test results: The results are as follows Figure 4 As shown, orlistat, inactivated CICC24917 and inactivated Amuci-5 can significantly reduce the fat content in zebrafish, and the effect of inactivated Amuci-5 on improving zebrafish obesity is better than that of inactivated CICC24917. Inactivated Amuci-7 and Amuci-8 failed to effectively inhibit zebrafish fat synthesis.

[0099] Example 8 Effect of live Akkermansia muciniphila Amuci-5 on improving obesity in DIO mice

[0100] Experimental grouping and administration: 48 SPF male C57BL / 6J mice aged 4-5 weeks and weighing 17-19g were purchased from Sichuan Weitong Lihua Experimental Animal Technology Co., Ltd. and kept in an SPF animal room. After 7 days of adaptive feeding, the mice were randomly divided into 6 groups according to their body weight, namely normal control group, model control group, orlistat group, B420 (isolated from commercial probiotics with fat-reducing effects, purchased from Evolution Health Pty. Ltd) group, CICC24917 group and Amuci-5 group, with 8 mice in each group. The normal control group was fed with ordinary maintenance feed, and the other groups were fed with high-fat feed (60kcal% fat; D12492, purchased from ResearchDiets Inc) for 8 consecutive weeks. During the experiment, the normal control group and the model control group were gavaged with 0.2 mL of lyophilized protective agent per rat; the positive control orlistat group was gavaged with 10 mL / kg body weight of orlistat (purchased from Zhien Biotechnology Co., Ltd.), with a dose of 40 mg / kg; the positive control B420 group, CICC24917 group, and Amuci-5 group were gavaged with 1×10 9CFU / 0.2mL / mouse, each group was given once a day. The experimental results were expressed as Mean±SEM, and one-way ANOVA was used for multiple comparison analysis. Compared with the model group, *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.

[0101] Body weight detection: all mice were weighed every Monday, and the body weight change rate and body weight gain were calculated; body weight change rate = (detected body weight - initial body weight) / initial body weight × 100%; body weight gain = detected body weight - initial body weight.

[0102] Body fat content detection: After the experimental period, the body composition analyzer (purchased from Suzhou Newmai Analytical Instrument Co., Ltd.) was used to detect the fat and lean meat content of mice, and the fat and lean meat content (fat weight / body weight, lean meat weight / body weight) was calculated.

[0103] Oral glucose tolerance test: To explore the effect of Akkermansia muciniphila on glucose tolerance in DIO mice, an OGTT test was performed 7 weeks after the experiment. After all mice were fasted overnight, blood was collected from the tip of their tails, and the fasting blood glucose concentration was measured using a blood glucose meter (purchased from Jiangsu Yuyue Medical Equipment Co., Ltd.). Subsequently, glucose (purchased from Shanghai Aladdin Biochemical Technology Co., Ltd.) was gavaged at a dose of 2 g / kg. The blood glucose concentration of the mice was measured at 30 min, 60 min, 90 min and 120 min, and the time-blood glucose concentration curve was drawn.

[0104] Test results: Figure 5 The body weight at the end of the experiment was significantly lower in the orlistat group, B420 group, and Amuci-5 group than in the model control group ( Figure 5 A), Orlistat, B420, CICC24917 and Amuci-5 groups could significantly reduce the weight gain of DIO mice ( Figure 5 B, C), Amuci-5 is more effective in controlling body weight gain than the standard strain CICC24917.

[0105] Figure 6 The results of body fat test showed that orlistat and Amuci-5 could significantly reduce the fat mass of obese mice ( Figure 6 A), Amuci-5 is more effective in reducing fat mass than the standard strain CICC24917; Orlistat and Amuci-5 can significantly reduce the fat body ratio of obese mice ( Figure 6 B), Amuci-5 was better than the standard strain CICC24917 in reducing fat body ratio; the lean meat amount and lean meat / body weight ratio of B420 group, CICC24917 group and Amuci-5 group were not significantly different from those of the model group ( Figure 6C, D), the lean meat / body weight ratio in the orlistat group was significantly higher than that in the model control group ( Figure 6 D).

[0106] Figure 7 The results of the oral glucose tolerance test (OGTT) were analyzed. The area under the curve (AUC) of the OGTT curve showed that the AUC of the Amuci-5 group was significantly lower than that of the model control group ( Figure 7 B), indicating that Amuci-5 can effectively improve glucose intolerance in DIO mice.

[0107] Example 9: Effect of inactivating Akkermansia muciniphila Amuci-5 on improving obesity in DIO mice

[0108] Experimental grouping and administration: 40 SPF male C57BL / 6J mice aged 4-5 weeks and weighing 17-19g were purchased from Sichuan Weitong Lihua Experimental Animal Technology Co., Ltd. and kept in an SPF animal room. After 7 days of adaptive feeding, the mice were randomly divided into 5 groups according to their body weight, namely normal control group, model control group, orlistat group, inactivated CICC24917 group and inactivated Amuci-5 group, with 8 mice in each group. The normal control group was fed with ordinary maintenance feed, and the other groups were fed with high-fat feed (60kcal% fat; D12492, purchased from Research Diets Inc) for 8 consecutive weeks. During the experiment, the normal control group and the model control group were gavaged with 0.2mL / mouse lyophilized protective agent; the positive control orlistat group was gavaged with 10mL / kg body weight of orlistat (purchased from Zhien Biotechnology Co., Ltd.) at a dose of 40mg / kg; the inactivated CICC24917 group and the inactivated Amuci-5 group were gavaged with 1×10 9 CFU / 0.2mL / mouse, each group was given once a day. The experimental results were expressed as Mean±SEM, and one-way ANOVA was used for multiple comparison analysis. Compared with the model group, *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.

[0109] Body weight detection, body fat content detection, body fat content detection: same as Example 8.

[0110] Test results: Figure 8 The body weight at the end of the experiment was significantly lower in the orlistat group, inactivated CICC24917 group, and inactivated Amuci-5 group than in the model control group ( Figure 8 A), orlistat group, inactivated CICC24917 group and inactivated Amuci-5 group could significantly reduce the weight gain of DIO mice ( Figure 8B). The inactivated Amuci-5 is more effective in controlling the weight gain of DIO mice than the inactivated standard strain CICC24917 ( Figure 8 B, C).

[0111] Fig. 9 The results of body fat test showed that the fat mass of the orlistat group, inactivated CICC24917 group and inactivated Amuci-5 group was significantly lower than that of the model control group ( Fig. 9 A), the inactivated Amuci-5 group had a better effect on reducing fat mass than the inactivated standard strain CICC24917; the lipid body ratio of the orlistat group and the inactivated Amuci-5 group was significantly lower than that of the model control group ( Fig. 9 B), the inactivated Amuci-5 group was better than the inactivated standard strain CICC24917 in reducing the lipid body ratio; there was no significant difference in lean meat content among the groups ( Fig. 9 C), the lean meat / body weight ratio in the orlistat group was significantly higher than that in the model control group ( Fig. 9 D), and the other groups had no significant effect on the lean meat / body weight ratio ( Fig. 9 D).

[0112] Fig.10 The results of the oral glucose tolerance test (OGTT) showed that the blood glucose concentration of mice in each group increased sharply within 30 minutes after oral administration of glucose. Inactivated CICC24917 and inactivated Amuci-5 could significantly reduce the blood glucose concentration at 30 minutes ( Fig.10 C); At 60 minutes, the blood glucose concentrations in the inactivated CICC24917 and inactivated Amuci-5 groups were significantly lower than those in the model control group ( Fig.10 D). The area under the curve (AUC) analysis of the OGTT curve showed that the AUC of the inactivated CICC24917 group and the inactivated Amuci-5 group were significantly lower than that of the model control group ( Fig.10 B), indicating that both inactivated CICC24917 and inactivated Amuci-5 can effectively improve glucose intolerance in DIO mice, and the overall improvement effect of inactivated Amuci-5 is slightly better than that of the inactivated standard strain CICC24917 group.

[0113] Example 10 Therapeutic effect of Akkermansia muciniphila Amuci-5 on 5-fluorouracil-induced diarrhea in mice

[0114] Experimental animals: SPF male Balb / c mice, weighing 18-22 g, were purchased from Sichuan Weitonglihua Experimental Animal Technology Co., Ltd. and kept in an SPF animal room.

[0115] Experimental design: 5-FU (5-fluorouracil, purchased from Tianjin Jinyao Pharmaceutical Co., Ltd., specification 10mL / tube, 0.25g / 10mL) solution was used to induce a chemotherapy-related diarrhea model in mice. The mice were randomly divided into normal control group, model control group, positive control loperamide group and Amuci-5 strain group according to their initial body weight, with 5 mice in each group.

[0116] The total experimental period was 8 days, recorded as D1-D8. A single 5-FU modeling treatment was performed on D3. Except for the normal control group, which was intraperitoneally injected with normal saline, all other groups were treated with a single 5-FU intraperitoneal injection modeling treatment. The modeling dose was administered according to body weight (350 mg / kg).

[0117] All groups were given drugs by gavage. The normal control group and the model control group were gavaged with normal saline for 8 consecutive days (D1-D8). The positive control group was gavaged with loperamide (purchased from Xi'an Janssen Pharmaceutical Co., Ltd.) for 8 consecutive days (D1-D8, 20 mg / kg) according to body weight. The test strain group was gavaged for 8 consecutive days (D1-D8) with 1×10 9 CFU / test strain. The test was terminated after the administration on D8. The specific test groups and dosing regimens are shown in Table 2 below.

[0118] Table 2 Experimental groups and dosing regimens.

[0119]

[0120] Note: 5-FU: 5-fluorouracil; CFU: colony forming unit; d: day

[0121] Diarrhea observation and scoring: Place mice in a mouse cage lined with clean filter paper, 1 per cage. Hard stools and normal stools are scored as 0 points; mild, slightly wet stools or soft stools are scored as 1 point; moderate, wet stools, unformed stools and unclean perianal area are scored as 2 points; severe, loose stools and severe unclean perianal area are scored as 3 points. During the experimental period, the feces of mice were observed and scored every day. The total diarrhea score was the sum of the daily diarrhea scores.

[0122] The results show that Fig.11 As shown in Figure 2, compared with the model control group, the Amuci-5 administration group had a significant improvement effect on 5-FU-induced diarrhea ( Fig.11 A), the total diarrhea score was significantly reduced ( Fig.11 B).

[0123] Conclusion: The Akkermansia muciniphila Amuci-5 of the present invention has an obvious therapeutic effect on 5-FU-induced diarrhea in mice.

[0124] Example 11 Therapeutic effect of Akkermansia muciniphila on mice with radiation enteritis

[0125] Experimental design: 28 male C57BL / 6 mice were purchased from Chengdu Yaokang Biotechnology Co., Ltd. and kept in an SPF animal room. They were randomly divided into a normal control group, a model control group, a loperamide (purchased from Xi'an Janssen Pharmaceutical Co., Ltd., 15 mg / kg; 10 ml / kg) group, and a CICC24917 (1×10 9 CFU / mouse / day; 200uL / mouse) group, Amuci-5 (1×10 9 CFU / mouse / day; 200uL / mouse) group, 5-6 mice in each group, a total of 5 groups. Except for the normal control group, all other groups of mice were subjected to a single full abdominal X-ray irradiation, with an irradiation dose of 11.5Gy, and the irradiation day was defined as D0. The overall test period was from D-2 to D10, a total of 13 days. Each group was gavaged and administered once a day for 12 consecutive days. The experimental grouping and dosing regimen are shown in Table 3.

[0126] Table 3 Experimental groups and dosing regimens for treating radiation enteritis in mice

[0127]

[0128] During the experiment, general health observations were performed every day, including but not limited to the animals' appearance, behavior, breathing, glandular secretion, feces, etc. The diarrhea of ​​each animal after irradiation modeling was observed and recorded, and scored. After administration on D9, the animals were fasted but not watered overnight, and peripheral blood was collected on D10 for routine blood tests.

[0129] Diarrhea observation and scoring: Same as Example 10.

[0130] Blood routine test: Whole blood samples were collected from each group of animals through the vein for hemoglobin content (HGB) test (veterinary automatic blood cell analyzer, model: BC-2800Vet; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.). The results are expressed as Mean ± SEM, and one-way ANOVA was used for multiple comparison analysis. Compared with the model group, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.

[0131] Test results:

[0132] In terms of diarrhea scores, Fig.12 As shown, loperamide and Amuci-5 significantly reduced the D5 diarrhea score and D9 total diarrhea score of the model mice ( Fig.12 B, C). The effect of Amuci-5 in improving diarrhea is comparable to that of loperamide and superior to that of the standard strain CICC24917.

[0133] In terms of blood routine, Fig.13As shown, loperamide and Amuci-5 significantly improved the percentage of peripheral blood lymphocytes in model mice ( Fig.13 Amuci-5 significantly improved the increase in the percentage of neutrophils in the peripheral blood of model mice ( Fig.13 B); Amuci-5 significantly improved the increase in the percentage of peripheral blood mononuclear cells in model mice ( Fig.13 C), Amuci-5 significantly improved the decreased level of hemoglobin in the peripheral blood of model mice ( Fig.13 D).

[0134] It can be seen that Amuci-5 can significantly improve diarrhea, immunodeficiency, inflammatory stimulation and anemia in mice with radiation enteritis.

[0135] Example 12 21-day subacute toxicity test of Akkermansia muciniphila Amuci-5 strain

[0136] Strain sample preparation:

[0137] Transfer the Amuci-5 strain of Akkermansia muciniphila from the glycerol tube to 3 ml of anaerobic BHI & mucin liquid culture medium and culture at 37 °C for 48 hours for strain activation. Inoculate the activated strain into 360 mL of anaerobic BHI & mucin liquid culture medium, culture at 37 °C for about 60 hours, transfer to a 500 mL centrifuge tube, centrifuge at 8000 rpm / min for 10 minutes, and discard the supernatant. Resuspend the bacteria three times with 35 mL of anaerobic saline, take the resuspended bacterial solution and spot it on the hemocytometer for microscopic counting and record the data to ensure that the concentration of the bacterial solution is not less than 1.25×10 9 CFU / mL. Aliquot the bacterial solution after turbidity adjustment and counting into 10mL anaerobic tubes, 5mL per tube, for a total of 6 tubes.

[0138] Preparation of inactivated bacterial solution: Select 3 tubes and place them in a 70℃ water bath for 30 min for pasteurization.

[0139] Experimental Design:

[0140] The pathogenicity of the inactivated Akkermansia muciniphila Amuci-5 strain was evaluated with reference to the "Technical Guidelines for Safety Testing and Evaluation of Bacteria for Health Food Raw Materials (2020 Edition)" in the "Test Methods for Pathogenicity of Bacteria for Health Food Raw Materials". 30 ICR mice aged 4 to 5 weeks, half male and half female, 14 to 16 g for males and 15 to 17 g for females, were purchased from Sichuan Weitong Lihua Experimental Animal Technology Co., Ltd. After 3 days of feeding during the adaptation period, mice weighing 18 to 22 g were selected and divided into 3 groups, namely the control group, the live bacteria Amuci-5 group and the inactivated Amuci-5 group, with 10 mice in each group, half male and half female. The experimental period was 21 days. The day of grouping was D0. After grouping, mice in each group were fasted overnight (16 h). The day of administration was D1. From D1 to D3, the test substance was gavaged at a dosage volume of 20 mL / kg for 3 consecutive days. The control group was gavaged with normal saline, and the live bacteria Amuci-5 group was gavaged with a concentration of 1.90×10 10 CFU / mL, the intragastric concentration of the inactivated Amuci-5 group was 1.90×10 10 CFU / mL, (the guidelines require that the concentration of the test substance should not be less than 1.25×10 9 CFU / mL), and the food was fed 3-4h after the first oral administration. The observation was continued for 21 days starting from the first day of administration.

[0141] Clinical observation: Observe and record any abnormalities in the mouse's skin and fur, eyes and mucous membranes, breathing, limb movements, behavior, etc. Observe whether there are any tremors, convulsions, diarrhea, lethargy, drooling, and coma.

[0142] The results showed that in the 21-day observation of female and male mice in each group, each mouse had clean skin, smooth and shiny fur, normal eye mucosa, stable and normal breathing, normal limb movement, and normal behavior. No toxic reactions such as tremor, convulsion, diarrhea, lethargy, drooling, and coma occurred.

[0143] Body weight test: Weigh and record the body weight of all mice before and after the experiment. The results are expressed as Mean ± SEM and analyzed by T test.

[0144] The results are as follows Fig.14 As shown in the figure, the body weight of male or female mice in each group increased steadily during the experiment. At 21 days, there was no significant difference in the body weight of male or female mice in the live and inactivated Akkermansia muciniphila groups compared with the control group.

[0145] Result judgment criteria: If the animals in the test group do not show symptoms of poisoning or die during the test, and there is no statistically significant difference in indicators such as body weight compared with the control group, the strain can be determined to be non-pathogenic; if the animals in the test group show symptoms of poisoning or die during the test, or there is a significant difference in indicators such as body weight compared with the control group during the test, the strain can be determined to be pathogenic.

[0146] Conclusion: All vital signs of male or female mice in each group were normal during the experiment, weight gain was stable, and no toxic reactions or deaths occurred. At 21 days, there was no statistical difference in body weight between the two groups. In summary, both live and inactivated Akkermansia muciniphila Amuci-5 strains were non-pathogenic.

Claims

1. A kind of Akkermansia muciniphila Amuci-5 with the deposit number of CCTCC NO: M 2024050 or its progeny strain, clone strain and pure culture.

2. The inactivated bacteria of Akkermansia muciniphila Amuci-5 or its progeny strains, cloned strains and pure cultures as claimed in claim 1 with a deposit number of CCTCC NO: M 2024050.

3. The method for culturing Akkermansia muciniphila Amuci-5 or its progeny strain, cloned strain and pure culture according to claim 1, which comprises inoculating Akkermansia muciniphila Amuci-5 or its progeny strain, cloned strain and pure culture into a culture medium, performing proliferation culture, and obtaining proliferated Akkermansia muciniphila.

4. A food composition, a health product composition or a pharmaceutical composition, comprising the Akkermansia muciniphila Amuci-5 or its progeny strain, cloned strain and pure culture according to claim 1, or the inactivated bacteria of the Akkermansia muciniphila Amuci-5 or its progeny strain, cloned strain and pure culture according to claim 2.

5. Use of Akkermansia muciniphila Amuci-5 or its progeny strain, cloned strain and pure culture according to claim 1 in the preparation of a medicament, wherein the medicament is used to lower cholesterol alone or in combination with other probiotics or in combination with other drugs, or to prevent / treat obesity, or to prevent / treat diarrhea caused by anti-tumor drugs, or to prevent / treat radiation-induced intestinal damage, or to prevent / treat diarrhea caused by radiotherapy.

6. The use according to claim 5, characterized in that The diarrhea caused by the anti-tumor drug is chemotherapy-related diarrhea.

7. The use according to claim 6, characterized in that The chemotherapy-related diarrhea is diarrhea caused by drugs whose active ingredients are selected from one or more of the following: 5-fluorouracil, tegafur, 5'-2'-deoxyuridine, capecitabine, S-1, paclitaxel, docetaxel, vinorelbine, cisplatin, carboplatin, nedaplatin, oxaliplatin, lobaplatin, cyclophosphamide, ifosfamide, melphalan, carmustine, and irinotecan.

8. Use of the inactivated bacteria of Akkermansia muciniphila Amuci-5 or its progeny strains, cloned strains and pure cultures as claimed in claim 2 in the preparation of a health product composition or a pharmaceutical composition for weight loss.

Citation Information

Cited By

  • Ackermansiella muciniphila for improving obesity and glycolipid metabolism

    CN120555307A